Prognostic Impact of Baseline High-Sensitivity C-Reactive Protein in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Based on Body Mass Index.
10.4070/kcj.2012.42.3.164
- Author:
Khurshid AHMED
1
;
Myung Ho JEONG
;
Rabin CHAKRABORTY
;
Kyung Hoon CHO
;
Doo Sun SIM
;
Young Joon HONG
;
Youngkeun AHN
;
Daisuke HACHINOHE
;
Myeong Chan CHO
;
Chong Jin KIM
;
Young Jo KIM
Author Information
1. Department of Cardiovascular Medicine, Chonnam National University College of Medicine, Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article
- Keywords:
C-reactive protein;
Overweight;
Obesity;
Body mass index;
Myocardial infarction
- MeSH:
Atherosclerosis;
Body Mass Index;
C-Reactive Protein;
Humans;
Inflammation;
Korea;
Myocardial Infarction;
Obesity;
Overweight;
Percutaneous Coronary Intervention;
Proportional Hazards Models;
Thinness
- From:Korean Circulation Journal
2012;42(3):164-172
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: Serum high sensitivity C-reactive protein (hs-CRP) is a marker of inflammation and may lead to the development of atherosclerosis, adversely affecting mortality. The aim of this study was to evaluate the relationship between baseline hs-CRP level and 12-month clinical outcomes in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) according to their body mass index (BMI) status. SUBJECTS AND METHODS: Using data from the Korea Acute Myocardial Infarction Registry from November 2005 to September 2008, a total of 8174 consecutive AMI patients were studied. Cox proportional hazard model revealed that higher baseline levels of hs-CRP was associated with 12-month all-cause mortality (p=0.045). To further understand this association, patients were divided into 3 groups based on their body mass index: 1) overweight/obese, 2) normal weight, and 3) underweight patients. Then each group was stratified into quartiles based on their hs-CRP. RESULTS: In overweight/obese patients, Cox model showed significant association of hs-CRP with 12-month mortality when adjusted for age and gender (p<0.001), however, after adjustment with multiple covariates, mortality was highest in the 4th quartile {HR 2.382, (1.079-5.259), p=0.032} though statistically insignificant (p=0.172). We observed no significant association of serum hs-CRP with 12-month mortality in normal weight (p=0.681) and underweight (p=0.760) patients. CONCLUSION: Higher baseline hs-CRP level (> or =4.08 mg/dL) in overweight/obese AMI patients showed significant association with 12-month all-cause mortality independent of other prognostic markers.
